Aethlon Medical (AEMD) Reports Q1 Loss Per Share of $0.18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Aethlon Medical Announces Fiscal 2016 First Quarter Results
August 13, 2015 4:05 PM EDTSAN DIEGO, Aug. 13, 2015 /PRNewswire/ --Â Aethlon Medical, Inc. (Nasdaq: AEMD), the pioneer in creating affinity biofiltration devices to treat life-threatening diseases, today announced results for the first quarter of fiscal 2016 ended June 30, 2015.
"In recent months, we executed a series a corporate milestones that improve the future outlook for our organization," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "We continued to strengthen our balance sheet through the completion of a $6 million equity financing and... More
